Merck & Co. & Regeneron Pharmaceuticals

Merck & Co.: Merck & Co. is a key player in the antibody therapeutics market, benefiting from the projected market growth.

Regeneron Pharmaceuticals: Regeneron is a key player in the antibody therapeutics market, benefiting from the projected market growth.

Merck & Co.: Merck & Co. struck a deal to cut prices, committing to sell its diabetes drugs Januvia, Janumet, and Janumet XR at 70% off list prices directly to US consumers and pledging $70 billion in US R&D and manufacturing investments.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals is expected to announce a deal with the Donald Trump administration after the holidays.

Merck & Co.: Merck & Co. is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Merck & Co.: Developer and manufacturer of Lipfendra; approval boosts its cardiovascular pipeline and revenue prospects.

Regeneron Pharmaceuticals: Co-developer of injectable PCSK9 inhibitor Praluent; may see reduced demand.

Merck & Co.: Merck & Co. developed Ervebo, the only licensed Ebola vaccine, which the World Health Organization reviewed but recommended against deploying outside research settings for the Bundibugyo strain due to limited evidence.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals developed maftivimab, an experimental treatment prioritized by the World Health Organization for the Bundibugyo strain of Ebola, with supplies already in the Democratic Republic of the Congo.

Merck & Co.: Merck & Co.>>>'s Ervebo vaccine, effective against the Zaire strain of Ebola, is being considered for potential use against the Uganda — Bundibugyo strain, though its efficacy is still under assessment.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals has an antibody treatment, a component of Inmazeb, which was approved for the Ebola virus and is being prioritized for clinical trials against the Bundibugyo ebolavirus.